William J Sandborn Selected Research

Hemorrhage

4/2024	Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
2/2024	Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial.
12/2023	Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
1/2023	Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
1/2022	Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis.
1/2022	Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
1/2022	Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
1/2021	Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis.
1/2021	Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab.
9/2020	Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William J Sandborn Research Topics

Disease

247	Crohn Disease (Crohn's Disease) 04/2024 - 01/2002
223	Ulcerative Colitis 04/2024 - 04/2002
112	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2024 - 01/2002
49	Infections 12/2023 - 12/2002
31	Necrosis 01/2023 - 02/2003
31	Inflammation (Inflammations) 01/2023 - 05/2002
28	Hemorrhage 04/2024 - 12/2005
28	Neoplasms (Cancer) 02/2024 - 04/2002
15	Colitis 03/2023 - 04/2002
15	Body Weight (Weight, Body) 10/2022 - 11/2004
13	Fistula 01/2019 - 09/2002
10	Ulcer 10/2023 - 04/2012
10	Rheumatoid Arthritis 01/2022 - 05/2002
9	Abdominal Pain (Pain, Abdominal) 04/2024 - 08/2013
9	Pouchitis 01/2022 - 04/2002
8	Tuberculosis (Tuberculoses) 12/2023 - 12/2002
8	Herpes Zoster 04/2023 - 10/2009
8	Skin Neoplasms (Skin Cancer) 04/2023 - 04/2014
8	Diarrhea 12/2019 - 11/2002
7	Pathologic Constriction (Stenosis) 10/2023 - 05/2004
7	Obesity 01/2021 - 01/2017
7	Colorectal Neoplasms (Colorectal Cancer) 05/2017 - 01/2006
7	Delayed Hypersensitivity (Hypersensitivity, Type IV) 05/2010 - 05/2002
6	Opportunistic Infections (Opportunistic Infection) 04/2023 - 04/2008
6	Proctitis 11/2022 - 05/2012
6	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 05/2015
6	Lymphoma (Lymphomas) 01/2022 - 01/2002
5	Headache (Headaches) 01/2023 - 08/2003
5	Sepsis (Septicemia) 08/2022 - 04/2009
5	Abscess 01/2019 - 01/2009
5	Disease Progression 01/2016 - 02/2006
4	Pulmonary Embolism 04/2023 - 01/2018
4	Melanoma (Melanoma, Malignant) 04/2023 - 01/2019
4	Venous Thrombosis (Deep-Vein Thrombosis) 04/2023 - 11/2019
4	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 03/2023 - 06/2003
4	Arthralgia (Joint Pain) 01/2023 - 02/2006
4	Injection Site Reaction 01/2022 - 02/2006
4	Hypersensitivity (Allergy) 01/2019 - 10/2004
4	Multiple Sclerosis 01/2018 - 01/2004
4	Leukopenia 01/2018 - 07/2003
4	Weight Loss (Weight Reduction) 01/2018 - 11/2002

Drug/Important Bio-Agent (IBA)

75	Infliximab (Remicade)FDA Link 12/2021 - 05/2002
61	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2023 - 05/2002
53	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2024 - 08/2002
51	vedolizumabIBA 04/2024 - 01/2004
44	Monoclonal AntibodiesIBA 12/2023 - 05/2002
42	Adalimumab (Humira)FDA Link 11/2022 - 02/2003
34	Tumor Necrosis Factor InhibitorsIBA 01/2023 - 01/2004
31	C-Reactive ProteinIBA 01/2024 - 12/2003
31	Mesalamine (Mesalazine)FDA LinkGeneric 01/2022 - 01/2002
28	Ustekinumab (CNTO 1275)FDA Link 02/2024 - 10/2008
28	Biomarkers (Surrogate Marker)IBA 12/2023 - 07/2003
27	tofacitinibIBA 04/2023 - 08/2012
25	Certolizumab Pegol FDA Link 01/2022 - 02/2003
24	Azathioprine (Imuran)FDA LinkGeneric 07/2022 - 01/2002
22	Immunosuppressive Agents (Immunosuppressants)IBA 12/2023 - 12/2003
19	IntegrinsIBA 04/2024 - 11/2003
19	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2024 - 11/2008
17	Janus Kinase InhibitorsIBA 04/2023 - 08/2012
17	SteroidsIBA 01/2020 - 09/2002
17	Budesonide (Pulmicort)FDA LinkGeneric 12/2017 - 01/2002
15	golimumab FDA Link 01/2023 - 01/2014
15	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 08/2022 - 01/2002
14	Immunologic Factors (Immunomodulators)IBA 04/2024 - 12/2008
13	AntibodiesIBA 11/2021 - 02/2003
12	Interleukin-12 (IL 12)IBA 10/2022 - 05/2002
10	CytokinesIBA 01/2022 - 05/2002
10	Interleukin-23 (Interleukin 23)IBA 01/2022 - 10/2008
8	Phenobarbital (Luminal)FDA Link 10/2023 - 05/2006
8	Natalizumab (Tysabri)FDA Link 01/2018 - 05/2002
7	InterleukinsIBA 01/2023 - 03/2015
7	ozanimodIBA 01/2022 - 01/2016
6	ontamalimabIBA 12/2023 - 01/2017
6	Serum AlbuminIBA 10/2022 - 04/2012
6	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 10/2007
6	risankizumabIBA 01/2022 - 01/2017
6	Methotrexate (Mexate)FDA LinkGeneric 01/2021 - 12/2002
5	Prostaglandins AIBA 01/2024 - 01/2016
5	etrolizumabIBA 01/2023 - 07/2014
5	Proteins (Proteins, Gene)FDA Link 01/2023 - 05/2002
5	AlbuminsIBA 01/2021 - 01/2013
5	LactoferrinIBA 01/2020 - 06/2003
5	Sulfasalazine (Azulfidine)FDA LinkGeneric 04/2010 - 01/2002
4	omega-Chloroacetophenone (Mace)IBA 02/2024 - 01/2019
4	etrasimodIBA 01/2024 - 01/2020
4	Sphingosine-1-Phosphate ReceptorsIBA 01/2024 - 01/2020
4	guselkumabIBA 12/2023 - 01/2022
4	Janus KinasesIBA 04/2023 - 09/2014
4	mirikizumabIBA 01/2023 - 01/2020
4	Opiate AlkaloidsIBA 01/2023 - 01/2021
4	Janus Kinase 1IBA 01/2022 - 01/2020
4	upadacitinibIBA 01/2022 - 01/2020
4	Bile Acids and Salts (Bile Acids)IBA 01/2020 - 08/2006

Therapy/Procedure

222	Therapeutics 04/2024 - 01/2002
31	Biological Therapy 01/2023 - 05/2002
17	Colectomy 10/2021 - 04/2002
15	Remission Induction 01/2020 - 01/2002
9	Restorative Proctocolectomy 01/2022 - 09/2002
6	Aftercare (After-Treatment) 01/2022 - 10/2009
5	Drug Therapy (Chemotherapy) 01/2020 - 12/2005